Entry Point Capital, LLC Ultragenyx Pharmaceutical Inc. Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RARE
# of Institutions
288Shares Held
88.3MCall Options Held
505KPut Options Held
198K-
Vanguard Group Inc Valley Forge, PA9.78MShares$499 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$286 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.35MShares$273 Million0.68% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$232 Million0.03% of portfolio
-
Rtw Investments, LP New York, NY3.26MShares$166 Million2.24% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.57B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...